TAS102 in Combination With NAL-IRI in Advanced GI Cancers

NCT03368963 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Adenocarcinoma
Gastric Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Non-Resectable Cholangiocarcinoma
Stage IV Colorectal Cancer
Stage IV Gastric Cancer
Stage IV Pancreatic Cancer
Stage IVA Colorectal Cancer
Stage IVB Colorectal Cancer
Stage III Colorectal Cancer
Stage III Gastric Cancer
Stage III Pancreatic Cancer
Unresectable Digestive System Adenocarcinoma
Unresectable Pancreatic Carcinoma

Interventions

DRUG: Nanoliposomal Irinotecan
DRUG: Trifluridine and Tipiracil Hydrochloride

Sponsor

Emory University

Collaborators

[object Object]
[object Object]